Search Our Website:

Ed Allera, Shareholder in the firm's FDA & Biotechnology section, recently represented Breckenridge Pharmaceutical Inc. and Nexgen Pharma Inc. in their fight against the FDA's attempt to rescind its 20-year-old approval of their generic laxative drug. The FDA ordered a halt to sales by May 2 but extended the deadline to November 2. Ed comments on the decision and next steps in Law360's "MiraLAX Generics Get FDA Reprieve Despite Bayer Objections."